Celgene, Acceleron Announce Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes Presented at ASH 2018 Met The Primary Endpoint Of Red Blood Cell Transfusion Independence (RBC-TI) For 8 Or More Weeks During The First 24 Weeks Of The Study.